Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial have?
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial has 45 citations in the OpenAlex counts ScholarIQ stores.
When was Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial published?
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial has 2022 year in the ScholarIQ index.
What is the open-access status of Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial?
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial has bronze oa status in the ScholarIQ index.
What is the DOI of Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial?
The DOI for Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial is on the source record.
What is the PMID of Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial?
The PMID for Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial is on the source record.
What is the OpenAlex record for Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial?
The OpenAlex for Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial is on the source record.